📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT (2019)

First Author: Pushpakom S
Attributed to:  Renewal of the Network of Hubs for Trials Methodology Research. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3310/eme06060

PubMed Identifier: 31318501

Publication URI: http://europepmc.org/abstract/MED/31318501

Type: Journal Article/Review

Parent Publication: Efficacy and Mechanism Evaluation

Issue: 6